www.fdanews.com/articles/175715-novartis-cosentyx-superior-to-rival-stelara
![Novartis logo](https://www.fdanews.com/ext/resources/test/Drug-Images2/Novartis.gif?t=1631046727&width=430)
Novartis' Cosentyx Superior to Rival Stelara
March 11, 2016
In head-to-head trials, Novartis’ interleukin-17A inhibitor Cosentyx was more effective than Johnson & Johnson’s Stelara in retaining skin clearance in adults with moderate-to-severe plaque psoriasis.
Results from the 52-week study demonstrated that Cosentyx exhibited a superior rapid onset of action versus Stelara, but had a similar safety profile, Novartis said. Stelara recently was approved for the treatment of psoriatic arthritis and ankylosing spondylitis in the EU and U.S.